Masimo (NASDAQ: MASI), a global leader in medical technology, has announced a partnership with Qualcomm Technologies, Inc. to develop a next-generation smartwatch reference platform for original equipment manufacturers (OEMs) focused on Wear OS by Google smartwatches. This collaboration integrates Masimo’s advanced biosensing technologies with Qualcomm’s Snapdragon wearable platforms, aiming to bolster the Wear OS ecosystem […]
Masimo (NASDAQ: MASI) has made an advancement in consumer health technology with the announcement of US Food and Drug Administration (FDA) clearance for MightySat Medical. This marks a significant milestone as MightySat Medical becomes the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) directly to consumers without the need for a prescription. […]
Masimo (NASDAQ: MASI) has announced the FDA 510(k) clearance of the Masimo W1 medical watch for both over-the-counter (OTC) and prescription use. This groundbreaking approval makes Masimo W1 the first FDA-cleared watch to provide continuous, real-time monitoring of oxygen saturation (SpO2) and pulse rate (PR). Expanding the Reach of Masimo W1 in Medical Settings and […]
Masimo, a US medical device company, has received clearance from the US Food and Drug Administration (FDA) for Centroid, the company’s wearable, wireless patient orientation, activity, and respiration rate sensor. Centroid is said to aid clinicians in monitoring patient position to avoid preventable pressure ulcers. Besides, it can alert clinicians to sudden movements like fall-like […]
